Quantcast
Last updated on April 23, 2014 at 11:18 EDT

Latest Beta amyloid Stories

Alzheimer's Disease Drug Stopped Mid-Trial
2013-06-17 05:08:38

Lee Rannals for redOrbit.com - Your Universe Online Eli Lilly & Co has ended a clinical trial for an Alzheimer's disease drug during the middle of the study after patients showed abnormal liver biochemical tests. The company announced last week that it would be putting a halt to its LY2886721 drug trial. LY2886721, the code-name for the drug, was designed to inhibit beta secretase, which contributes to the buildup of amyloid plaque in the brain that is believed to cause Alzheimer's....

2013-06-13 16:27:02

Decision does not impact other Lilly Alzheimer's compounds in development INDIANAPOLIS, June 13, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced it has stopped its Phase II study (BACC) for LY2886721, a beta secretase (BACE) inhibitor being investigated as a once daily treatment for its potential to slow the progression of Alzheimer's disease. The decision to terminate the study was due to abnormal liver biochemical tests. Clinical study investigators have...

2013-06-13 10:06:12

Mount Sinai researchers find reduction in brain plaques in mice after treatment with drugs currently prescribed for other indications Multiple drug classes commonly prescribed for common medical conditions are capable of influencing the onset and progression of Alzheimer's disease, according to researchers at The Mount Sinai Medical Center. The findings are published online in the journal PLoS One. Led by Giulio Maria Pasinetti, MD, PhD, the Saunders Family Chair and Professor in...

Researchers Quantify Brain Protein Changes In Alzheimer Patients
2013-06-13 08:30:44

April Flowers for redOrbit.com - Your Universe Online A significant and potentially pivotal difference between the brains of patients with an inherited form of Alzheimer's disease and healthy family members who do not have it has been measured by researchers at Washington University School of Medicine in St. Louis. Researchers have long known that a protein fragment called amyloid beta builds up into plaques in Alzheimer´s patient´s brains. The theory is that these plaques...

2013-06-13 00:22:58

NEW YORK, June 12, 2013 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) announced that it has awarded follow-on funding of $298,500 to Madera Biosciences, Inc. to further develop its small molecule drugs designed to clear accumulated beta-amyloid from the brain and thus halt or reverse the progression of Alzheimer's disease. Madera has identified a series of proprietary, small molecule compounds that increase the expression of apolipoprotein E (apoE), which has...

2013-06-12 23:02:20

Mount Sinai researchers find reduction in brain plaques in mice after treatment with drugs currently prescribed for other indications. New York, NY (PRWEB) June 12, 2013 Multiple drug classes commonly prescribed for common medical conditions are capable of influencing the onset and progression of Alzheimer´s disease, according to researchers at The Mount Sinai Medical Center. The findings are published online in the journal PLoS One. Led by Giulio Maria Pasinetti, MD, PhD, the Saunders...

2013-06-11 14:53:38

Healthy test subjects with amyloid plaque were also found to have hypometabolism indicating a potential Alzheimer´s precursor Alzheimer´s disease has been linked in many studies to amyloid plaque buildup in the brain, but new research is finding a common thread between amyloid burden and lower energy levels, or metabolism, of neurons in certain areas of the brain associated with Alzheimer´s disease–even for people with no sign of cognitive decline. This is a new...

2013-06-06 12:28:45

BERLIN, BOSTON and MUMBAI, India, June 6, 2013 /PRNewswire/ -- Piramal Imaging announced today that results from four studies evaluating the Company's PET amyloid imaging agent (florbetaben F18(*)) will be presented at the 2013 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI 2013) taking place in Vancouver from June 8-12. Additionally, Andrew Stephens, Vice President of Clinical Research and Development at Piramal Imaging will present an update and highlights...

2013-06-04 08:29:34

ZARAGOZA, Spain, June 4, 2013 /PRNewswire/ -- Alzheimer researchers in Spain have taken a step closer to finding a blood test to help in the diagnosis of Alzheimer's disease. With approximately 75% of the estimated 36 million Alzheimer's sufferers worldwide yet to receive a reliable diagnosis, the potential impact on the lives of possible sufferers, present and future, could be huge. Alzheimer's disease is a neurodegenerative disease most frequently affecting the...

2013-05-29 10:13:32

Scientists at the University of Liverpool and Callaghan Innovation in New Zealand have developed a new chemical approach to help harness the natural ability of complex sugars to treat Alzheimer's disease. The team used a new chemical method to produce a library of sugars, called heparan sulphates, which are known to control the formation of the proteins in the brain that cause memory loss. Heparan sulphates are found in nearly every cell of the body, and are similar to the natural...